The world's first: Grand Pharma's global innovative product STC3141 successfully reached the clinical endpoint in the Phase II clinical study in China

Grand Pharmaceutical Group Limited Denmark Finland Germany Netherlands Sweden United Kingdom Hong Kong New York California France

The results showed that the SOFA scores of the drug treatment groups on the 7th day were significantly lower than those of the baseline, especially in the high-dose group, where the decrease was significantly greater than that in the placebo group, of which the difference was statistically significant and clinically significant.The trend of the secondary endpoints was consistent with the primary endpoints, which was in line with expectations.STC3141 is the first sepsis treatment program centered on rebuilding immune homeostasis in the world, achieving a major upgrade in the treatment dimension.View original content:https://www.prnewswire.co.uk/news-releases/the-worlds-first-grand-pharmas-global-innovative-product-stc3141-successfully-reached-the-clinical-endpoint-in-the-phase-ii-clinical-study-in-china-302448303.html